US Patent 3,939,178: Scope, Claims, Expiration and Patent Landscape for Etodolac-Type Pyranoindoles

US Patent 3,939,178 covers a broad genus of substituted tetrahydropyrano[3,4-b]indole and tetrahydrothiopyrano[3,4-b]indole compounds, including the nonsteroidal anti-inflammatory drug etodolac and related analogues. The patent issued February 17, 1976, and, under the pre-URAA patent-term rule, expired February 17, 1993, absent an earlier terminal disclaimer or other unusual term adjustment. It does not currently block manufacture, sale, or formulation of etodolac in the United States.

The patent’s commercial importance was historical. Its principal value was the early protection of a chemical platform that included 1-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid, the structure associated with etodolac. Current commercial risk is instead determined by later patents, regulatory exclusivity, manufacturing know-how, and any product-specific patents that may have existed around the original NDA.

What does US Patent 3,939,178 cover?

US 3,939,178 is a compound patent. Claim 1 covers a Markush genus defined by:

A fused tetrahydropyranoindole or tetrahydrothiopyranoindole core.
Substitution at the 1-position by lower alkyl, alkenyl, alkynyl, cycloalkyl, phenyl, benzyl, or 2-thienyl groups.
Optional alkyl substitution at positions identified as R2 through R5.
Broad substitution on the indole ring, including hydrogen, alkyl, hydroxy, alkoxy, benzyloxy, alkanoyloxy, nitro, halogen, mercapto, alkylthio, trifluoromethyl, amino, and sulfamoyl.
Hydrogen, alkyl, or alkenyl substitution at the nitrogen position.
An oxygen or sulfur atom in the pyrano or thiopyrano ring.
An acetic acid, propionic acid, butyric acid, carboxylic acid, ester, or related carbonyl-containing side chain.
Pharmaceutically acceptable salts.

The claim is drafted to capture a large chemical neighborhood rather than a single commercial compound. The dependent claims identify 56 named species, including acids, methyl and ethyl esters, sulfur analogues, ring-substituted analogues, and salts.

The structure image and one Markush alternative in the supplied transcription are represented by OCR placeholders. The written claim should therefore be read with the issued patent drawing and specification when conducting a formal infringement or validity opinion.

What is the relationship between US 3,939,178 and etodolac?

Etodolac is generally identified as 1-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid. That compound appears expressly in claim 5 and again in claim 30, with the latter containing a typographical variation in the supplied text.

Etodolac-related claim coverage

Claim	Compound or category	Commercial relevance
1	Broad Markush genus	Captures the overall chemical platform
5	1-Methyl pyranoindole-1-acetic acid	Direct etodolac species
30	Same or substantially same etodolac species	Duplicate or corrected species listing
6	Methyl ester	Prodrug or intermediate analogue
3	Ethyl ester	Ester analogue
7-8	Propionic acid and ethyl ester	Homologated side-chain analogues
9-10	Thiopyrano sulfur analogues	Bioisosteric analogues
33	Carboxylic acid analogue	Distinct side-chain variant
37	Benzylamine salt of hydroxy analogue	Salt and substituted derivative

The patent does not claim “etodolac” by brand name. It claims the chemical structure. A product containing the claimed active ingredient would have fallen within the patent during its enforceable term, regardless of whether it was sold under the Lodine brand.

How broad is claim 1?

Claim 1 has substantial chemical breadth, but its scope is constrained by the required core structure and substituent definitions.

Core scaffold limitation

The claim requires a fused tetrahydropyrano[3,4-b]indole or tetrahydrothiopyrano[3,4-b]indole framework. Compounds based on unrelated NSAID scaffolds, such as ibuprofen, naproxen, diclofenac, celecoxib, or indomethacin, do not fall within the literal chemical scope merely because they have anti-inflammatory activity.

The ring heteroatom is important. Claim 1 permits either:

Oxygen, producing a tetrahydropyranoindole; or
Sulfur, producing a tetrahydrothiopyranoindole.

This captures both the principal oxygen-containing series and sulfur bioisosteres.

Substituent breadth

The R1 definition is particularly broad. It includes:

Methyl, ethyl, propyl and other lower alkyl groups;
Alkenyl and alkynyl groups;
Lower cycloalkyl groups;
Phenyl;
Benzyl; and
2-Thienyl.

The dependent claims demonstrate how the patent uses this breadth. Claims 11 through 21 cover ethyl, propyl, isopropyl, tert-butyl, phenyl, and thienyl variants. Claims 22 through 29 and 43 through 57 add halogen, methoxy, methyl, nitro, trifluoromethyl, and other ring substitutions.

Acid, ester and salt coverage

The claim covers both free acids and pharmaceutically acceptable salts. Several dependent claims separately identify methyl and ethyl esters. This distinction matters in infringement analysis:

The free acid is a claimed compound.
A pharmaceutically acceptable salt can also be claimed.
An ester is covered only if it falls within the relevant carbonyl and Z definitions or a dependent claim.
A formulation containing a claimed compound may raise product infringement issues, but the patent does not independently claim tablets, capsules, coatings, excipients, or release profiles.

What do claims 2 through 57 add?

Claims 2 through 57 are species claims. Their principal legal function is to provide narrower fallback positions if the broad genus in claim 1 is challenged.

The claimed species cover five main groups.

Etodolac and close alkyl analogues

Claims 2, 4-8, 11-14, 16-20, 26-27, 30, 34, 38-42 and 44 cover variations at the 1-position, 4-position, 9-position, alpha carbon, and acid side chain. These claims include methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, and phenyl substitutions.

Ring-substituted analogues

Claims 22-29 and 43-57 cover:

Bromo;
Chloro;
Methoxy;
Acetoxy;
Benzyloxy;
Hydroxy;
Nitro;
Methyl;
Ethyl; and
Trifluoromethyl substitution.

The ring-substitution claims expand the patent beyond etodolac itself and create a broader research-compound portfolio.

Nitrogen-substituted analogues

Claims 4, 34, 35 and 40-41 include methyl, ethyl, propyl and allyl substitution at the nitrogen position. These claims are directed to N-substituted analogues of the pyranoindole system.

Sulfur analogues

Claims 9, 10, 31 and 32 cover tetrahydrothiopyrano[3,4-b]indole compounds. These are chemically distinct from etodolac but remain within claim 1 because X may be oxygen or sulfur.

Salts and protected derivatives

Claim 37 covers a benzylamine salt of a hydroxy-substituted compound. The salt claim confirms that the patent contemplated pharmaceutical salt forms, while the acetoxy and benzyloxy claims cover protected or functionalized ring substituents.

When did US Patent 3,939,178 expire?

Event	Date or status
US patent issued	February 17, 1976
Applicable term rule	17 years from grant for a pre-June 8, 1995 application
Projected ordinary expiration	February 17, 1993
Current status	Expired
Current blocking effect	None, based on the patent’s expiration

The patent predates the 20-year term measured from the earliest effective nonprovisional filing date under the Uruguay Round Agreements Act. The ordinary term was therefore measured from grant rather than filing date. The patent is now far beyond its maximum ordinary term.

Patent expiration eliminates enforceable patent rights under this patent. It does not retroactively eliminate infringement occurring during the enforceable period, nor does it resolve separate rights under later patents.

What Orange Book status does US 3,939,178 have?

US 3,939,178 should not be treated as a current Orange Book barrier. The patent expired in 1993, and the Food and Drug Administration’s Orange Book does not confer renewed exclusivity on an expired patent.

Etodolac products have been approved through the abbreviated new drug application and new drug application systems. Etodolac is a small molecule, so the relevant regulatory pathway is the ANDA pathway rather than the biosimilar pathway. FDA product and patent records must be distinguished:

Orange Book listing concerns patents submitted for approved drug products.
Patent expiration determines whether the listed patent remains enforceable.
FDA approval does not extend an expired composition-of-matter patent.
A later formulation or method-of-use patent could have a different expiration date, but it would not revive US 3,939,178.

The patent itself contains no claim to a specific dosage form, labeling statement, tablet coating, controlled-release profile, or pharmaceutical composition.

Did US 3,939,178 create Paragraph IV risk?

During its enforceable term, a generic applicant seeking approval for a product containing a claimed compound could have faced a Paragraph IV certification if the patent had been listed for the relevant reference product. The applicant would have needed to certify that the patent was invalid, unenforceable, or would not be infringed.

That issue is now historical for this patent. A Paragraph IV certification against an expired patent does not create a present launch barrier. A generic applicant may also use a Paragraph III certification where a listed patent remains valid but has not expired. That distinction no longer changes the outcome for US 3,939,178.

Likely historical Paragraph IV theories

A Paragraph IV challenge during the patent term could have focused on:

Prior art against the pyranoindole genus.
Obviousness based on known indole and heterocyclic anti-inflammatory compounds.
Written-description support for the full breadth of the Markush substituents.
Enablement across the extensive range of substituents.
Definiteness of the chemically complex formula and OCR-sensitive definitions.
Anticipation of the specific etodolac species.
Obviousness of the claimed salts, esters, or sulfur analogues.

The patent’s age means those defenses now have little commercial value except in historical litigation or damages analysis.

What formulation patents protect etodolac products?

US 3,939,178 does not claim a formulation. It claims compounds and salts.

A product-specific patent landscape would normally be divided into:

Patent category	Covered subject matter	Relevance to current generic entry
Composition of matter	Etodolac and analogues	Covered by 3,939,178 historically; expired
Salt or polymorph	Solid-state or salt form	Potentially relevant only if separately patented
Formulation	Tablet, capsule, coating, excipient or release profile	Requires separate patent identification
Method of use	Treatment of pain, inflammation or a specific condition	Requires separate patent identification
Manufacturing process	Synthesis, purification or crystallization	May create process-level risk
Regulatory exclusivity	FDA exclusivity periods	Separate from patent term; historical for the original product

No formulation, method-of-use, manufacturing, or polymorph claim should be attributed to US 3,939,178 without a separate patent document.

What manufacturing and intellectual-property barriers existed?

The patent’s manufacturing impact was strongest while it was in force. A competitor could not lawfully make the claimed active compound in the United States without a license, even if it used a different synthetic route. A design-around would have required either:

A compound outside the claim 1 scaffold;
A substituent outside the listed Markush categories;
A different ring fusion or heteroatom arrangement;
A structurally distinct acid side chain; or
A noninfringing process where only a process claim, rather than the compound itself, presented risk.

Because US 3,939,178 is a product claim patent, changing the manufacturing route would not avoid infringement if the resulting product remained within a claimed species. After expiration, the remaining barriers are primarily technical and commercial:

Process yield and impurity control;
Control of stereochemistry, if relevant;
Crystallization and particle-size specifications;
API regulatory qualification;
DMF support;
Bioequivalence;
Supply reliability; and
Any separate later patent or trade-secret restrictions.

Which companies challenged or commercialized etodolac?

Etodolac was commercialized as Lodine and subsequently supplied by multiple generic manufacturers. The originator and later commercial participants have included companies associated with the A.H. Robins, American Home Products, Wyeth, and generic pharmaceutical sectors.

The relevant competitive set is the broader NSAID market:

Drug	Primary scaffold	Patent position today	Commercial relationship to etodolac
Etodolac	Pyranoindole acetic acid	Original compound patent expired	Direct generic competition
Ibuprofen	Propionic acid	Legacy patents expired	Low-cost NSAID substitute
Naproxen	Naphthalene propionic acid	Legacy patents expired	Competing oral NSAID
Diclofenac	Phenylacetic acid derivative	Legacy patents expired; later products may have separate rights	Competing NSAID
Celecoxib	Diaryl pyrazole	Original composition patent expired; later patents varied	COX-2 selective competitor
Meloxicam	Oxicam	Legacy composition rights expired in major markets	Competing chronic-use NSAID

The principal commercial consequence of expiration was the transition from originator exclusivity to multi-source generic competition.

How strong is the patent estate for US 3,939,178?

Historical strength

The patent had meaningful historical strength because claim 1 combined:

A defined and relatively unusual fused heterocycle;
Broad substitution at multiple positions;
Oxygen and sulfur ring variants;
Acid, ester and salt coverage; and
Numerous expressly claimed species.

The dependent species claims improved litigation resilience by providing narrower claims that could survive even if the broad genus were narrowed or invalidated.

Current strength

Current enforceability is zero because the patent has expired. Its present value is limited to:

Historical freedom-to-operate review;
Patent-family mapping;
Prior-art analysis;
Chain-of-title research;
Interpretation of later continuation or improvement patents; and
Damages or litigation history.

The patent cannot independently prevent a generic launch today.

What patent litigation and settlement issues affect the patent?

No current litigation or settlement can be inferred from the claim text alone. The patent’s expiration also means that any historic litigation would not create a current launch restriction unless a separate surviving patent was involved.

A complete historical litigation review would distinguish:

Infringement actions involving the original compound;
ANDA litigation involving an etodolac reference product;
Challenges to later formulation or method patents;
License or settlement agreements;
Patent-term or terminal-disclaimer disputes; and
Cases involving unrelated pyranoindole compounds.

Settlement agreements can impose commercial restrictions between named parties, but they do not extend the statutory term of an expired patent against the public.

Does etodolac face biosimilar risk?

No. Etodolac is a chemically synthesized small-molecule drug. Biosimilar provisions under the Public Health Service Act apply to biological products, not conventional NSAIDs such as etodolac.

The relevant competitive risk is generic substitution through ANDAs. Generic applicants must demonstrate pharmaceutical equivalence and bioequivalence, subject to applicable FDA requirements. They do not need to repeat the full clinical development program required for an innovator NDA.

What geographic coverage did the patent have?

US 3,939,178 provided rights only in the United States. International protection would have required separate national or regional patents derived from the same priority disclosure.

The US expiration date does not establish expiration dates in:

Europe;
Canada;
Japan;
Australia;
India; or
Other jurisdictions.

Foreign family members may have had different filing dates, prosecution outcomes, claim scope, term adjustments, supplementary protection certificates, or abandonment histories. Those rights would need separate country-by-country review.

What generic launch scenarios existed and what is the current outlook?

The historical launch scenarios were:

Launch after ordinary patent expiration.
Early launch after a successful Paragraph IV challenge.
Launch under a settlement agreement.
Launch after designing around a later formulation or method patent.
Launch with a noninfringing product or indication.

For US 3,939,178, the relevant scenario is complete expiration. The patent no longer delays generic entry. Current market exposure depends on the number of approved generic suppliers, reimbursement, API cost, product discontinuations, and any later-listed patents associated with a particular etodolac product.

Key Takeaways

US 3,939,178 is a broad compound patent covering substituted tetrahydropyranoindoles, tetrahydrothiopyranoindoles, esters, acids, and pharmaceutical salts.
Etodolac is expressly identified in claims 5 and 30.
The patent issued February 17, 1976, and ordinarily expired February 17, 1993.
It contains no formulation, manufacturing-process, method-of-use, dosage-form, or biologic claims.
Paragraph IV risk is historical because the patent is expired.
Etodolac is a small molecule and has no biosimilar pathway.
Current US generic entry is not blocked by this patent.
Later formulation, polymorph, method-of-use, process, or regulatory patents must be analyzed separately.
International patent rights cannot be determined from the US patent alone.
The patent’s historical value was its broad chemical-platform coverage; its current enforceable value is zero.

FAQs

What active ingredient is covered by US Patent 3,939,178?

The patent covers etodolac and numerous related pyranoindole and thiopyranoindole compounds. Etodolac is the 1-methyl pyranoindole acetic acid species identified in claims 5 and 30.

Can a company manufacture etodolac under US 3,939,178 today?

Yes, the patent’s US term has expired. Separate rights under later patents, regulatory requirements, contractual restrictions, or third-party intellectual property must still be assessed independently.

Does the patent cover etodolac sodium or another etodolac salt?

Claim 1 includes pharmaceutically acceptable salts. Whether a particular salt falls within the claim depends on the active moiety, salt identity, and the full issued claim construction.

Does US 3,939,178 cover extended-release etodolac tablets?

Not expressly. The patent is directed to chemical compounds and salts. An extended-release formulation would require separate formulation claims to create distinct patent protection.

Is US 3,939,178 relevant to etodolac API suppliers outside the United States?

The patent had US territorial scope only. It does not independently restrict manufacturing or sales outside the United States, although corresponding foreign patents could have created separate national rights.

References

U.S. Patent and Trademark Office. (1976). U.S. Patent No. 3,939,178, Pyranocarboxylic acids. U.S. Department of Commerce.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.
U.S. Patent and Trademark Office. (1999). American Inventors Protection Act and patent term provisions. U.S. Department of Commerce.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	198787	⤷ Start Trial
Australia	4255472	⤷ Start Trial
Australia	463079	⤷ Start Trial
Belgium	784284	⤷ Start Trial
Bulgaria	60660	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 3,939,178